KGK Science
CompanyCanada
KGK Science develops 2 assets, the furthest in phase 2 (Mitopure in chronic obstructive pulmonary disease). Mostly supplement acting on Mitochondrial biogenesis (PGC-1α), autophagy and sirtuin signalling; based in Canada.
- 2
- Assets
- Furthest stage
- Phase 2
- 2
- Trials
- 17
- Signals
Pipeline
2Promotes mitophagy to remove damaged mitochondria and improve mitochondrial function.
Phase 2, Supplement, Mitochondrial biogenesis (PGC-1α), Autophagy, chronic obstructive pulmonary disease, aging (Phase 1), Partner
Nicotinamide riboside acts as an NAD+ precursor to increase NAD+ levels.
Phase 1, Supplement, Mitochondrial biogenesis (PGC-1α), Sirtuin signalling, fatigue, pharmacokinetic
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms6
- Trials4
- Signals20
- Similar companies6